Mycenax becomes Taiwan's first CDMO company to complete the CHO-S and CHOZN GS Cell Line Development with the Beacon(R) Optofluidic System
PR NewswireMay 18, 2021
TAIPEI, May 18, 2021 /PRNewswire/ -- Mycenax (TWSE: 4726) becomes one of the first CDMO companies in Asia to adapt the Beacon Optofluidic system to cell line development services. Mycenax adopted Beacon® Optofluidic System, a high throughput selection system for single-cell cloning and quantification with image evidence to support monoclonality, for cell line development service in 2020. Thousands of cells need to be screened to sought out the rare and high-productive clones in cell lin